Upon a certain DNA damage including cisplatin treatment, p73 is stabilized and exerts its growth-suppressive and/or proapoptotic function. However, the precise molecular basis by which the intracellular levels of p73 are regulated remains unclear. In the present study, we have identified RanBPM as a novel binding partner of p73a by yeastbased two-hybrid screening, and also found that RanBPM has an ability to stabilize p73a. GST pull-down assays and co-immunoprecipitation experiments revealed that RanBPM directly bound to the extreme COOH-terminal region of p73a, whereas it failed to interact with p53. Coexpression of RanBPM with p73a resulted in the nuclear translocation of RanBPM, and both proteins co-localized in cell nucleus as examined by indirect immunofluorescent staining. It is worth noting that the expression of RanBPM inhibited the ubiquitination of p73a, and thereby prolonged its half-life. Subsequent studies demonstrated that the proapoptotic activity of p73a was significantly enhanced in the presence of RanBPM. Taken together, our present findings implicate a novel role for RanBPM in the regulation of p73 stability and function. Oncogene (2005) 24, 938-944.
Upon a certain DNA damage including cisplatin treatment, p73 is stabilized and exerts its growth-suppressive and/or proapoptotic function. However, the precise molecular basis by which the intracellular levels of p73 are regulated remains unclear. In the present study, we have identified RanBPM as a novel binding partner of p73a by yeastbased two-hybrid screening, and also found that RanBPM has an ability to stabilize p73a. GST pull-down assays and co-immunoprecipitation experiments revealed that RanBPM directly bound to the extreme COOH-terminal region of p73a, whereas it failed to interact with p53. Coexpression of RanBPM with p73a resulted in the nuclear translocation of RanBPM, and both proteins co-localized in cell nucleus as examined by indirect immunofluorescent staining. It is worth noting that the expression of RanBPM inhibited the ubiquitination of p73a, and thereby prolonged its half-life. Subsequent studies demonstrated that the proapoptotic activity of p73a was significantly enhanced in the presence of RanBPM. Taken together, our present findings implicate a novel role for RanBPM in the regulation of p73 stability and function. Oncogene Keywords: p53; p73; RanBPM; two-hybrid; ubiquitination p73 is a newly identified p53-related nuclear transcription factor, and functions to promote cell cycle arrest and/or apoptosis (Kaghad et al., 1997) . These cellular roles of p73 are largely attributed to its ability to transactivate specific target genes. In contrast to p53, p73 is expressed as multiple isoforms arising from either alternative splicing or alternative promoter usage (Melino et al., 2002) . Although functional differences among the splicing isoforms with different COOHtermini remain unclear, NH 2 -terminally truncated forms of p73 (DNp73) have an oncogenic potential and exhibit a dominant-negative behavior toward wild-type p73 as well as p53 (Pozniak et al., 2000; Nakagawa et al., 2002; Stiewe et al., 2002) .
Steady-state levels of p73 are kept extremely low under normal conditions, however, p73 is significantly induced at protein level in response to a certain genotoxic stress including cisplatin treatment, which is mediated by a nuclear nonreceptor tyrosine kinase c-Abl (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . c-Abl binds to the PXXP motif of p73 and phosphorylates p73 at Tyr-99. Alternatively, Ren et al. (2002) reported that protein kinase Cd catalytic fragment phosphorylates p73 at Ser-289, and increases its stability, suggesting that posttranslational modification such as phosphorylation might contribute to increase the stability of p73. Protein phosphorylation has been shown to be involved in the initiation of protein ubiquitination by E3 ubiquitin ligase (Carrano et al., 1999; Ganoth et al., 2001) . As described previously (Balint et al., 1999; Lee and La Thangue, 1999) , p73 is regulated at least in part by the protein degradation process through the ubiquitin-proteasome system. Additionally, Lee and La Thangue (1999) described that the COOH-terminal region of p73a might have a regulatory role in the proteasome-dependent degradation of p73. Recently, we have found that MM1 and RACK1 interact with the extreme COOH-terminal region of p73a, and regulate its transcriptional activity as well as proapoptotic function Ozaki et al., 2003) . However, these interactions did not have a detectable effect on the intracellular levels of p73a.
To identify the possible cellular protein(s) involved in the regulation of p73 protein stability, we screened a cDNA library derived from human fetal brain using the extreme COOH-terminal region of p73a (amino-acid residues 551-636) as a bait in a yeast-based two-hybrid system. After screening of approximately 5 Â 10 5 transformants, 12 independent clones exhibited a high level of b-galactosidase activity, and subsequent sequence analysis revealed that three out of them encoded the overlapping regions of RanBPM (Figure 1a) . RanBPM was initially identified as a cellular protein that can interact with Ran nuclear-cytoplasmic transport protein (Nakamura et al., 1998; Nishitani et al., 2001) , and contained the putative SPRY domain which might be involved in protein-protein interactions (Ponting et al., 1997) . Although most of the Ran-binding proteins play an important role in nucleocytoplasmic transport, it is unlikely that RanBPM is involved in this process (Nishitani et al., 2001) . Alternatively, Nakamura et al. (1998) reported that RanBPM might be involved in reorganization of the microtubule network; however, the precise function of RanBPM remains unknown.
Consistent with the previous observations (Rao et al., 2002) , RanBPM was expressed in various cell lines (Figure 1b) . To confirm the interaction between RanBPM and p73, we performed GST pull-down assays using a GST fusion protein containing RanBPM (Invitrogen, Carlsbad, CA, USA) , and generated cDNAs were amplified by PCR in the presence of primers specific for p73 (top panel), RanBPM (middle panel) or GAPDH (bottom panel). (c) GST pull-down assay. In vitro translated 35 Slabeled p73a, p73b, p73a (1-548) or p53 was incubated with bacterially expressed GST or for 2 h at 41C. Bound complexes were recovered on the glutathione-sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ, USA), washed extensively with the binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Nonidet P-40, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride), and then boiled in SDS sample buffer. Bound proteins were resolved by 10% SDS-polyacrylamide gel, and analysed by autoradiography. The input of the radio-labeled proteins used in the binding reaction is also shown. (d) p73a interacts with RanBPM in mammalian cultured cells. COS7 cells transfected with the indicated expression plasmids were lysed in 25 mM TrisHCl, pH 8.0, 137 mM NaCl, 1% Triton X-100 and 1 mM phenylmethylsulfonyl fluoride. Whole-cell lysates were immunoprecipitated with anti-p73 antibody (Ab-4, NeoMarkers, Fremont, CA, USA) or anti-FLAG (M2, Sigma, St Louis, MO, USA), and subjected to immunoblotting with anti-FLAG (first panel) or with anti-HA (12CA5, Roche Molecular Biochemicals, Indianapolis, IN, USA) antibody (second panel), respectively. Separate aliquots of the lysates were immunoblotted with anti-p73 (third panel) or anti-FLAG antibody (fourth panel) to confirm the expression of FLAG-RanBPM or HA-p73a, respectively. (e) COOH-terminal region of p73a is required for the interaction with RanBPM. COS7 cells were co-transfected with the indicated combinations of the expression plasmids, and whole-cell lysates were immunoprecipitated with anti-HA antibody, followed by immunoblotting with anti-FLAG antibody (top panel). Cell lysates were immunoblotted as a control for FLAG-RanBPM (middle panel), HA-p73a and HA-p73a derivatives (bottom panel) in the input lysate. (f) p53 does not bind to RanBPM. Cell lysates prepared from COS7 cells transfected with FLAG-RanBPM were immunoprecipitated with the normal mouse serum (NMS, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) or anti-p53 antibodies (DO-1 plus PAb1801, Oncogene Research Products, Cambridge, MA, USA). Immunoprecipitates were analysed by immunoblotting with anti-FLAG antibody (right panel). Left panels show the Western blotting with anti-FLAG, or anti-p53 antibody to monitor the expression level of FLAG-RanBPM or the endogenous p53, respectively Stabilization of p73 by RanBPM S Kramer et al and in vitro translated 35 S-labeled p73a, p73b, p73a(1-548) or p53. GST alone was employed as a negative control. As shown in Figure 1c , radio-labeled p73a was pulled down by GST-RanBPM(112-408) but not by GST alone. However, p73b and p73a(1-548), which lack the extreme COOH-terminal portion of p73a, were no longer able to interact with . In addition, p53 failed to bind to . In good agreement with the yeast two-hybrid results, these observations suggest that the extreme COOH-terminal portion of p73a is responsible for the physical interaction with RanBPM. Next, we performed co-immunoprecipitation experiments to confirm their interaction in cells. To this end, cell lysates prepared from COS7 cells co-transfected with HAtagged p73a and FLAG-tagged full-length RanBPM were immunoprecipitated with anti-p73 or anti-FLAG antibody, followed by immunoblotting with anti-FLAG or anti-HA antibody, respectively. As shown in Figure 1d , HA-p73a co-immunoprecipitated with FLAG-RanBPM. Under our experimental conditions, HA-p73a(1-427) and HA-p73a(1-247) did not coimmunoprecipitate with FLAG-RanBPM (Figure 1e ). In contrast to full-length p73a, the anti-p53 immunoprecipitates did not contain FLAG-RanBPM (Figure 1f ). Taken together, our results suggest that RanBPM has an ability to interact with p73a but not with p53 in mammalian cultured cells.
Previous immunostaining studies have shown that p73a is exclusively localized in cell nucleus (Jost et al., 1997) , while RanBPM could distribute to the cell nucleus, perinuclear region and cytoplasm (Nishitani et al., 2001; Umeda et al., 2003) . To examine the subcellular localization of RanBPM in the presence or absence of p73a, COS7 cells were transfected with the indicated expression plasmids, and the indirect immunofluorescent staining was performed. As shown in Figure 2a and b, FLAG-RanBPM and HA-p73a were detected largely in the cytoplasm and cell nucleus, respectively. Of note, when FALG-RanBPM was coexpressed with HA-p73a, a fraction of FLAG-RanBPM translocated into cell nucleus, and co-localized with nuclear HA-p73a (Figure 2c-e) . To confirm this issue, transfected COS7 cells were fractionated into nuclear and cytoplasmic fractions, and their subcellular localizations were analysed by immunoblotting. The purity of the nuclear and cytoplasmic fractions was examined by immunoblotting with anti-Lamin B and anti-a-tubulin antibody, respectively. Consistent with the indirect immunofluorescent staining, co-expression of FLAGRanBPM with HA-p73a resulted in a significant nuclear accumulation of FLAG-RanBPM, whereas FLAGRanBPM alone was detected in the cytoplasmic fraction (Figure 2f ). In addition, the amounts of nuclear HAp73a seemed to be increased in the presence of FLAGRanBPM. It is thus likely that RanBPM interacts with p73a in cell nucleus, and could affect the stability of p73a.
To test whether RanBPM could affect the stability of p73a, COS7 cells were co-transfected with the constant amount of HA-p73a together with or without the increasing amounts of FLAG-RanBPM. As shown in Figure 3a , the amount of HA-p73a was markedly increased in the presence of FLAG-RanBPM in a dose-dependent manner, whereas the expression level of p73a mRNA remained unchanged. On the other hand, FLAG-RanBPM had no significant effect on the levels of exogenous p53 (Figure 3b) . Similar results were also obtained in p53-deficient H1299 cells (data not shown). We next sought to determine the half-life of p73a in the presence of RanBPM. For this purpose, COS7 cells were transfected with HA-p73a together with or without FLAG-RanBPM. At 24 h after transfection, cells were treated with cycloheximide. At the indicated time periods, cell lysates were analysed for HA-p73a by immunoblotting. In accordance with the previous reports (Lee and La Thangue, 1999; Ohtsuka et al., , ectopically expressed p73a had a half-life of less than 4 h, whereas the degradation rate of HA-p73a was slower in FLAG-RanBPM-expressing cells (Figure 3c ). Thus, it is likely that the RanBPM-dependent stabilization of p73a is attributed to the clear increase in the halflife of p73a.
As described (Balint et al., 1999) , the stability of p73 is regulated at least in part through the ubiquitinproteasome pathway. These observations prompted us to determine whether RanBPM could prevent the ubiquitination of p73. COS7 cells were transfected with HA-p73a-and His-tagged ubiquitin, or in combination Figure 3 RanBPM increases the stability of p73 but not of p53. (a) RanBPM increases the amounts of p73a. COS7 cells were cotransfected with the constant amount of HA-p73a (0.5 mg) together with or without the increasing amounts of FLAG-RanBPM (0.5, 1.0 and 1.5 mg). The total amount of plasmid DNA was kept constant (2 mg) with pcDNA3. At 48 h after transfection, cell lysates or total RNA were prepared, and subjected to immunoblotting with the indicated antibodies (upper panels) or RT-PCR analysis (lower panels). Immunoblotting for actin (20-33, Sigma Chemical Co.) serves as a loading control. (b) RanBPM does not affect the amounts of p53. COS7 cells were co-transfected with the indicated combinations of the expression plasmids, and were processed for immunoblotting as described above. (c) RanBPM increases the half-life of p73a. COS7 cells were transfected with HA-p73a alone (0.5 mg) (left panels) or together with FLAG-RanBPM (1.5 mg) (right panels). At 24 h post-transfection, cells were treated with cycloheximide (100 mg/ml) and harvested at the indicated time periods. Cell lysates were used for immunoblotting with the indicated antibodies. The intensity of the bands was quantified by using densitometry. (d) RanBPM inhibits the ubiquitination of p73a. COS7 cells were co-transfected with the constant amount of HA-p73a (0.5 mg) and His-tagged ubiquitin (Ub) (0.5 mg), together with or without the increasing amounts of FLAG-RanBPM (0.5, 1.0 and 1.5 mg). At 24 h post-transfection, cells were treated with 20 mM MG-132 for 6 h before being harvested. His-tagged ubiquitin-containing protein complexes were pulled down with Ni 2 þ -agarose beads (QIAGEN, Valencia, CA, USA), and subsequently resolved by 10% SDS-polyacrylamide gel electrophoresis, followed by immunoblotting with anti-p73 antibody Stabilization of p73 by RanBPM S Kramer et al with the increasing amounts of FLAG-RanBPM. At 24 h after transfection, cells were treated with MG-132 for 6 h. His-ubiquitinated proteins were purified by Ni 2 þ -agarose beads, and then analysed by immunoblotting with the anti-p73 antibody. As shown in Figure 3d , the slower migrating ubiquitinated forms of p73a were detectable in the absence of FLAG-RanBPM. Intriguingly, the ubiquitination levels of p73a were significantly reduced in cells expressing FLAG-RanBPM, suggesting that RanBPM stabilizes p73a by inhibiting its ubiquitination.
To determine whether RanBPM could affect the transcriptional activity of p73a, H1299 cells were transiently transfected with a constant amount of the expression plasmid for HA-p73a, together with the p53/ p73-responsive p21 WAF1 or MDM2 luciferase reporter constructs in the presence or absence of increasing amounts of the FLAG-RanBPM expression plasmid. As shown in Figure 4a , expression of FLAG-RanBPM enhanced the ability of p73a to transactivate the p21
WAF1
and MDM2 promoters in a dose-dependent manner. To extend the functional significance of their interaction, we examined the possible effect of RanBPM on the p73a-mediated apoptosis. H1299 cells were transfected with HA-p73a, FLAG-RanBPM, or HA-p73a and FLAGRanBPM. The b-galactosidase was used as a marker to visualize the transfected cells. At 48 h post transfection, the number of b-galactosidase-positive cells was scored. As shown in Figure 4b , the number of b-galactosidasepositive cells expressing FLAG-RanBPM was similar to that detected in the empty plasmid-transfected cells. Consistent with the previous report , expression of HA-p73a resulted in a clear decrease in the number of b-galactosidase-positive cells. Of note, co-expression of HA-p73a with FLAGRanBPM significantly reduced the number of b-galactosidase-positive cells as compared with that observed in cells expressing HA-p73a alone. In addition, we performed a colony formation assay. H1299 cells were transfected with HA-p73a, FLAG-RanBPM or HAp73a plus FLAG-RanBPM, and the transfected cells were selected in the presence of G418. After 2 weeks of selection, drug-resistant colonies were fixed and stained with Giemsa's solution. In accordance with the bgalactosidase assay, FLAG-RanBPM expression did not affect the colony formation as compared with the empty plasmid-transfected control, whereas co-expression of HA-p73a with FLAG-RanBPM reduced the colony formation even more efficiently than HA-p73a alone (Figure 4c ). Considering that p73a efficiently induced apoptosis in H1299 cells (Di Como et al., 1999; Zeng et al., 1999) , these results suggest that RanBPM increases the proapoptotic activity of p73a. To further confirm this issue, H1299 cells were transiently transfected with a constant amount of the GFP expression plasmid along with the indicated combinations of the expression plasmids. At 48 h after transfection, transfected cells were identified by fluorescence microscopy for the appearance of green fluorescence, and the number of GFP-positive cells with condensed and fragmented nuclei was counted. As shown in Figure 4d , co-expression of HA-p73a with FLAG-RanBPM increased the number of apoptotic cells as compared with that resulting from expression of HA-p73a alone. Taken together, our present results strongly suggest that RanBPM-mediated stabilization of p73a is critical for its effects on transcriptional activation as well as apoptosis.
Recently, it has been shown that a variety of cellular proteins could interact with RanBPM, including MET, androgen receptor, HIPK2, USP11, Twa1, calbindin D28K and p75 NTR , suggesting that RanBPM is involved in diverse biological processes (Ideguchi et al., 2002; Rao et al., 2002; Wang D et al., 2002; Wang Y et al., 2002; Bai et al., 2003; Lutz et al., 2003; Umeda et al., 2003) . In the present study, we demonstrated that RanBPM increased the stability of p73a by reducing its ubiquitination levels. An important question raised by our results is how RanBPM stabilize p73a. Intriguingly, Ideguchi et al. (2002) described that RanBPM is associated with the deubiquitination enzyme USP11, which belongs to the ubiquitin hydrolase family. Considering that p53 is stabilized by direct deubiquitination by the deubiquitination enzyme HAUSP , it is likely that RanBPM could bind to USP11 and promote deubiquitination of p73a by recruiting USP11 to p73a; however, further studies will be required to determine this issue.
Alternatively, Lee and La Thangue (1999) found that p73b is much more stable than p73a, suggesting that the unique COOH-terminal portion of p73a might be critical for degradation by the ubiquitin-proteasome system. According to our present results, RanBPM bound to p73a through its extreme COOH-terminal region, whereas it failed to interact with p73b. Thus, it is plausible that RanBPM might increase the steady-state levels of p73a by masking p73a COOH-terminal lysine residues, which could be the sites for ubiquitin ligation, and/or disrupting the interaction of p73a with unknown proteins required for ubiquitination-mediated proteolysis. These possibilities are currently under investigation. Elucidation of the detailed molecular mechanism underlying the RanBPM-dependent stabilization of p73a would be necessary for better understanding of p73 turnover.
Another finding of the present study is that, under our experimental conditions, cytoplasmic RanBPM became nuclear in the presence of p73a overexpression. Given that RanBPM is localized in both the cytoplasm and nucleus (Nakamura et al., 1998; Nishitani et al., 2001) , it is probable that p73a might have an ability to promote nuclear translocation of RanBPM through the physical interaction between them. As described previously, wildtype p53 is predominantly localized in the cytoplasm of many neuroblastoma cells (Moll et al., 1996) . The abnormal cytoplasmic distribution of p53 might be attributed at least in part to the interaction with Parc, which acts as a cytoplasmic anchor protein for p53 (Nikolaev et al., 2003) . Interestingly, Goldschneider et al. (2004) found that enforced expression of p73a in neuroblastoma-derived SH-SY5Y cells significantly enhances the nuclear accumulation of wild-type p53 and . Total amount of plasmid DNA was kept constant (1 mg) with pcDNA3, and pcDNA3 alone was used as a negative control. At 2 days after transfection, cells were selected with G418 (400 mg/ml) for 2 weeks. G418-resistant colonies were fixed in methanol, and stained with Giemsa's solution. Representative dishes of three independent experiments are shown. (d) RanBPM enhances the p73a-mediated apoptosis. H1299 cells transfected with 0.2 mg of the GFP expression plasmid and 0.5 mg of the HA-p73a expression plasmid together with or without 1.5 mg of the FLAG-RanBPM expression plasmid. At 48 h after transfection, transfected cells were identified by the presence of green fluorescence. Cell nucleus was stained with DAPI to reveal nuclear condensation and fragmentation. The number of GFPpositive cells with apoptotic nuclei was scored Stabilization of p73 by RanBPM S Kramer et al restores its function, indicating that p73a displaces p53 from the cytoplasmic complex containing Parc. It is thus likely that p73a could modulate cellular proteins/pathways that specifically regulate nuclear import and export of RanBPM. Since RanBPM is associated with a variety of nuclear proteins, p73a might play a critical role in regulating nuclear function of RanBPM.
